Tag: Omnipod
Insulet’s Omnipod integrates with Libre
November 21, 2024HME News Staff
ACTON, Mass. – Insulet’s Omnipod 5 Automated Insulin Delivery System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring sensor in the U.S. “We are excited to announce that Omnipod 5, the only AID system indicated for both Type 1 and Type 2 diabetes, is now integrated with Abbott’s FreeStyle Libre 2 Plus sensor in the U.S.,” aid Eric Benjamin, Insulet’s executive vice president and chief product and customer experience officer....
Insulet sees ‘robust’ Q3
November 8, 2024HME News Staff
ACTON, Mass. – Insulet reported revenue of $543.9 million for the third quarter of 2023, an increase of 25.7%. Total Omnipod revenue was $533.6 million, an increase of 26.4%; of that, U.S. Omnipod revenue was $395.6 million and international Omnipod revenue was $138 million. “We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, president and CEO. “Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both...
Insulet: ‘2024 is shaping up to be another year of rapid growth’
August 13, 2024HME News Staff
ACTON, Mass. – Insulet has reported revenue of $488.5 million for the second quarter of 2024, a 23.2% increase year over year, exceeding the high end of the company’s guidance, driven by outperformance for all product lines.
Total Omnipod revenue was $480.4 million, a 26.3% increase, including $352.3 million in the U.S., a 27.3% increase.
“2024 is shaping up to be another year of rapid growth, fueled by strong Omnipod 5 demand and our accelerating pace of product...
Insulet reports earnings increase, gains market share
May 15, 2024HME News Staff
ACTON, Mass. – Insulet reported revenue of $441.7 million for the first quarter 2024, an increase of 23.3% compared to the prior year. Total Omnipod revenue was $433.0 million, an increase of 21.1%, with U.S. Omnipod revenue $317.7 million. “We are pleased with our strong first quarter results, which underscore the strength of our advanced technology platform and deep competitive advantages,” said Jim Hollingshead, president and CEO. “During the quarter, we achieved strong...
Health care goes OTC
April 26, 2024Theresa Flaherty, Managing Editor
As is par for the course these days, my inbox this month has been filled with diabetes tech announcements: Edgepark is adding a new insulin delivery system to its portfolio, Insulet’s Omnipod is fueling growth and Ascensia is expanding access to its Eversense device by extending its PASS program, which offers a substantial discount for users.
That last one is key: All the technology in the world won’t help if it’s too expensive for people to acquire. And this stuff is expensive...
Insulet’s Omnipod fuels growth
February 23, 2024HME News Staff
ACTON, Mass. – Insulet reported full year 2023 revenues $1.7 billion, up 30% compared to 2022. Fourth quarter 2023 revenue was $509.8 million, up nearly 38%. Total Omnipod revenue was $501 million; of that, US Omnipod revenue was $394.6 million, an increase of nearly 43%. “2023 was another transformational year for Insulet,” said Jim Hollingshead, president & CEO. “The rapid adoption of Omnipod 5 helped fuel our eighth consecutive year of more than 20% constant currency revenue...
Insulet gets FDA clearance for iPhone app
October 24, 2023HME News Staff
ACTON, Mass. – Insulet has received 510(k) clearance from the U.S. Food and Drug Administration for its Omnipod 5 App for iPhone, making Insulet the first company to offer a tubeless automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone. "Today, we celebrate this significant milestone in our ongoing effort to provide people with diabetes solutions that improve their lives and help them think less about diabetes," said Eric Benjamin, executive...
Insulet’s Omnipod 5 cleared for use ages two and up
August 24, 2022HME News Staff
ACTON, Mass. – Insulet has received U.S. Food and Drug Administration clearance for its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with Type 1 diabetes. “We received tremendous first-hand reports of how Omnipod 5 made diabetes management easier for our pivotal trial participants, and the clinical data demonstrated impressive glycemic improvements, as well,” said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet’s senior vice president and medical...
Insulet surpasses $1 billion in Omnipod revenue
February 25, 2022HME News Staff
ACTON, Mass. – Insulet Corporation reported revenue of $307.7 million for the fourth quarter of 2021, and full year revenue of $1.1 billion. Total Omnipod revenue was $275.8 million for the quarter and $1 billion for the full year. Of that, U.S. Omnipod revenue for the year was $651.5 million and international Omnipod revenue of $359.9 million. “2021 was another successful year for Insulet, as we reached an important milestone of over $1 billion in revenue and advanced our strategic priorities,”...
Insulet highlights ‘growing power’ of Omnipod
November 8, 2021HME News Staff
ACTON, Mass. – Insulet Corp. reported revenue of $275.6 million for the third quarter of 2021, up 17.8% over the same period last year.
It reported revenue was $260.3 million, up 22.7%, for Omnipod.
"Our third quarter results reflect the growing power of Omnipod,” said Shacey Petrovic, president and CEO. “We are driving global new customer starts, have momentum across our business, and are advancing exciting new innovations. We continue to share compelling clinical...